ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

This study has been terminated.
(MTD not determined)
Sponsor:
Information provided by (Responsible Party):
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT00407407
First received: December 1, 2006
Last updated: April 6, 2012
Last verified: August 2008
  Purpose

The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly and every 3-weeks ABI-007 in combination with carboplatin (area under the curve [AUC]=6) in patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.


Condition Intervention Phase
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Ovarian Neoplasms
Drug: ABI-007
Drug: Carboplatin
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study of ABI-007 With Carboplatin TM as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Resource links provided by NLM:


Further study details as provided by Celgene Corporation:

Primary Outcome Measures:
  • Primary: Safety/tolerability endpoints are the maximum tolerated dose and dose-limiting toxicities [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Safety-AEs, SAEs, Lab abnormalities, incidence of patients experiencing dose modification of those interruptions &/or premature of d/c pf study drug [ Time Frame: Patient progression or until discontinuation ] [ Designated as safety issue: Yes ]

Enrollment: 6
Study Start Date: November 2006
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: ABI-007
    80mg/m^2 to 150mg/m^2 IV every 3 weeks
    Drug: Carboplatin
    6 AUC IV every 3 weeks on the same day as ABI-007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a histological diagnosis of primary peritoneal carcinoma, fallopian tube or epithelial ovarian carcinoma (Stage III or IV) with either (optimal less than or equal to 1 cm) residual disease or suboptimal residual disease following initial appropriate surgery.
  • Patients with the following histologically confirmed types of ovarian cancer are eligible: serous cystadenocarcinoma, mucinous cystadenocarcinoma, clear cell adenocarcinoma, adenocarcinoma (unspecified), malignant Brenner's tumor, endometrioid adenocarcinoma, undifferentiated carcinoma, mixed epithelial carcinoma and transitional cell carcinoma. Patients with extraovarian papillary serous cystadenocarcinoma are eligible.
  • Patients who do not have measurable disease may be included and will be assessed for toxicity and progression-free survival only. Measurable disease is NOT required but when present will be followed to assess response. For patients to be evaluated for response of measurable disease, tumor must be greater than or equal to 2.0 cm with conventional computed tomography (CT) imaging or greater than or equal to 1.0 cm with spiral CT imaging.
  • No prior chemotherapy for ovarian cancer is permitted.
  • Patients must be entered no more than 12 weeks postoperatively.
  • ECOG performance status 0-2.
  • Age greater than or equal to 18 years.
  • Patient has the following blood counts at Baseline:

    • ANC greater than or equal to 1.5 x 10^9 cells/L;
    • Platelets greater than or equal to 100 x 10^9 cells/L;
    • Hemoglobin (Hgb) greater than or equal to 9 g/dL.
  • Patient has the following blood chemistry levels at Baseline:

    • AST (SGOT), ALT (SGPT) less than or equal to 2.5x upper limit of normal range (ULN);
    • Total bilirubin less than or equal to ULN;
    • Creatinine less than or equal to 1.5 mg/dL.
  • Peripheral neuropathy Grade 0 or 1 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).
  • It is assumed that almost all patients already had bilateral oophorectomy. However, if a female of childbearing potential, has a negative pregnancy test (within 72 hours of the first dose of study drug), the patient must agree to use an effective method to avoid pregnancy for the duration of the study.
  • Patients must have signed an approved informed consent and authorization permitting the release of personal health information.

Exclusion Criteria:

  • Patients who have received any prior treatment, other than initial debulking surgery, for the cancer being treated in this study. Patients may have received adjuvant chemotherapy for localized breast cancer, if the therapy was completed greater than or equal to 3 years before registration in this study and if the patient remains free of recurrent or metastatic disease.
  • Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis. Prior radiation for localized cancer of the breast, head and neck or skin is permitted if it was completed greater than or equal to 3 years before registration in this study and if the patient remains free of recurrent metastatic disease.
  • Concurrent immunotherapy or hormonal therapy for ovarian cancer.
  • Parenchymal brain metastases, unless documented to be clinically and radiographically stable for at least 6 months after treatment for the disease.
  • Serious intercurrent medical or psychiatric illness, including serious active infection (i.e. requiring antibiotics).
  • Patients with borderline or low malignant potential tumors.
  • History of other malignancy within the last 5 years, which could affect the diagnosis or assessment of ovarian cancer.
  • Patients who have received an investigational drug within the previous 3 weeks.
  • Patient is currently enrolled in a different clinical study in which investigational procedures are performed or investigational therapies are administered. Also, a patient may not enroll in such clinical trials while participating in this study.
  • Pregnant or nursing women.
  • Patients with unstable angina or those who have had myocardial infarction within the past 6 months. Patients with evidence of cardiac conduction abnormalities (e.g., bundle branch block, heart block) are eligible if their cardiac status has been stable for the 6 months prior to study entry.
  • Patients with prior hypersensitivity to both Taxol and Taxotere.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00407407

Locations
United States, Texas
University of Texas, MD Anderson Cancer Center
Houston, Texas, United States, 77230-1439
Sponsors and Collaborators
Celgene Corporation
Investigators
Principal Investigator: Robert Coleman, MD Univeristy of Texas, MD Anderson Cancer Center
  More Information

No publications provided

Responsible Party: Celgene Corporation
ClinicalTrials.gov Identifier: NCT00407407     History of Changes
Obsolete Identifiers: NCT00405223
Other Study ID Numbers: CA034
Study First Received: December 1, 2006
Last Updated: April 6, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Celgene Corporation:
Epithelial ovarian
Primary peritoneal or fallopian tube carcinoma
Abraxane
Carboplatin
primary peritoneal or fallopian tube carcinoma

Additional relevant MeSH terms:
Carcinoma
Fallopian Tube Neoplasms
Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms
Abdominal Neoplasms
Adnexal Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Peritoneal Diseases
Urogenital Neoplasms
Carboplatin
Paclitaxel
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014